BioWorld Today: News To Note-Aegerion Pharmaceuticals, Inc.
June 03, 2013 - BioWorld Today
Aegerion Pharmaceuticals Inc., of Cambridge, Mass., said the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion with a unanimous vote recommending a marketing authorization for Lojuxta (lomitapide) hard capsules. If approved, Lojuxta will be indicated as an adjunct to a lowfat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolemia (HoFH). A decision is expected from the European Commission in the third quarter of 2013.